Introduction
Cryptococcosis is a systemic mycosis that affects humans and a large number of mammals, which presents most commonly as life-threatening meningoencephalitis [1] . Currently the two etiologic agents of disease form a species complex, i.e., Cryptococcus neoformans and C. gattii . Molecular epidemiological studies have identifi ed eight major molecular types within this species complex. The molecular types of C. neoformans correlate with the serotypes as follows; VNI ( ϭ AFLP1) and VNII ( ϭ AFLP1A) correspond to serotype A, VNIII ( ϭ AFLP3) relates to the hybrid serotype AD, and Antifungal susceptibility studies have reported a wide range of results depending on the species, serotypes, or the methodology (CLSI microdilution or Etest) used [6 -10] . C. gattii was observed to be less susceptible than C. neoformans to itraconazole, fl uconazole, ravuconazole, voriconazole, ketoconazole [6, 7] , and amphotericin B [7] . In addition, the MICs for fl uconazole and amphotericin B obtained by the CLSI or Etest methods were signifi cantly lower for C. neoformans serotype D strains when compared to serotype A [8] . However, other studies have found no differences in the susceptibilities between the two species [9] and among their serotypes A, D, B and C relative to amphotericin B, fl uconazole, 5-fl uorocytosine and voriconazole [10] . The present study aimed to determine if these inconsistent results are random or if they correlate to molecular type differences by investigating 67 Brazilian isolates.
Materials and methods

Strains studied
Eighteen isolates of C. neoformans molecular type VNI, 11 C. gattii molecular type VGI and 38 C. gattii molecular type VGII recovered from the Pathogenic Fungal Culture Collection of the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, were included in the study. The majority were isolated from cerebrospinal fl uid (CSF; 61/67), and six from environmental sources (two VNI, one VGI and three VGII). Clinical VNI isolates were obtained from HIV positive (10) and HIV negative (fi ve) patients, while those of VGII were recovered from four HIV positive and 18 HIV negative patients. All clinical VGI isolates were obtained from HIV negative patients. For 14 isolates (one VNI and 12 VGII) the HIV status of the patients from which they were isolated was unknown.
Antifungal susceptibility testing
The broth microdilution method was used to determine the MIC values [11] , with a fi nal concentration of 0.5 ϫ 10 3 to 2.5 ϫ 10 3 cells/ml and RPMI 1640 medium buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic. Growth and sterility control wells were included for each isolate tested. The following antifungal drugs were obtained as assay powders; albaconazole (J. Uriach & Co, S.A., Barcelona, Spain), amphotericin B (E. R. Squibb & Sons, Barcelona, Spain), 5-fl uorocytosine (Hoffmann-La Roche, Basel, Switzerland), fl uconazole (Pfi zer, Madrid, Spain), itraconazole and ketoconazole (Janssen Research Foundation, Beerse, Belgium), ravuconazole (Bristol-Myers Squibb Company, New Brunswick, NJ, USA), and voriconazole (Pfi zer, Madrid, Spain). The MIC endpoints were read after 72 h of incubation at 35 ° C. The MIC of amphotericin B was defi ned as the lowest concentration that caused 100% inhibition of growth, and the MICs of all other antifungal drugs were described as the lowest concentrations that produced 50% reduction in growth as compared to controls. The Candida parapsilosis strain ATCC 22019 and the Candida krusei strain ATCC 6258 were included as controls each time that a set of isolates was tested.
Genotyping
The molecular types were determined by URA5 -RFLP analysis after amplifi cation of the URA5 gene from high molecular weight DNA. Amplifi cation of the URA5 gene was performed in a fi nal volume of 50 μ l. Each reaction contained 50 ng of DNA, 1 ϫ PCR buffer [160 mM (NH 4 ) 2 SO 4 , 670 mM Tris-HCI (pH8.8 at 25 ° C), 0.1% Tween-20 -Bioline], 0.2 mM each of dATP, dCTP, dGTP, and dTTP (Roche Diagnostics GmbH, Switzerland), 3 mM magnesium chloride, 1.5 U BioTaq DNA polymerase (Bioline, Australia), and 50 ng of each primer URA5 (5 ′ ATGTC-CTCCCAAGCCCTCGACTCCG 3 ′ ) and SJ01 (5 ′ TTAAGACCTCTGAACACCGTACTC 3 ′ ). PCR was performed for 35 cycles at 94 ° C with a 2 min initial denaturation, 45 s denaturation at 94 ° C, 1 min annealing at 61 ° C, 2 min extension at 72 ° C, and fi nal extension cycle for 10 min at 72 ° C. The obtained PCR products were then double digested with the endonucleases Sau 96I (10 U/ μ l) and Hha I (20 U/ μ l) for 3 h, and the fragments were separated by 3% agarose gel electrophoresis at 100 V 
Statistics
Statistical analysis was performed using the program SPSS version 11.0 software (LEAD technologies, USA), and a P -value Ͻ 0.05 was used to defi ne signifi cance. The Wilcoxon test or the Mann-Whitney test was used for comparisons among the molecular types.
Results
The geometric means (GM) MIC 90 and MIC ranges of the antifungal drugs tested are shown in Table 1 . The range of MICs for each drug was; Ͻ 0.03 -0.25 μ g/ml for albaconazole, 0.25 -2 μ g/ml for amphotericin B, Ͻ 0.03 -0.5 μ g/ml for itraconazole, 0.25 to Ͼ 64 μ g/ml for 5-fl uorocytosine, 0.25 to Ͼ 64 μ g/ml for fl uconazole, Ͻ 0.03 -0.25 μ g/ml for
The only drug for which no difference was found in the susceptibilities of the different molecular types was amphotericin B. This differs from the fi ndings reported by Khan et al . [7] , who observed that the C. gattii serotype B was less susceptible than the C. neoformans serotype A to amphotericin B. However, this study analyzed only environmental isolates from India and used a different method, the E-test, the results of which are not always compatible to the CLSI microdilution method [13] .
Results of other studies are similar to those described in this report, indicating that VGII is less susceptible to azoles regardless of the geographic region from which the isolates were obtained. A recent Australian study showed higher in vitro MIC ' s for the molecular type VGII than those found with VGI and the C. neoformans molecular types to voriconazole and fl uconazole [14] . In addition, their analysis of the susceptibility to fl uconazole showed that higher concentrations of drugs were needed to inhibit the growth of VGII isolates from the North and the West of Australia than the Vancouver Island (BC, Canada) outbreak VGIIa and VGIIb isolates [14] . Hagen et al. , investigating 350 C. gattii isolates from several countries, obtained similar results [15] . In their study the MIC values also varied according to the molecular types but did not vary with the geographical origin of the isolates. The VGII ( ϭ AFLP6) isolates were less susceptible than those of VGI ( ϭ AFLP4). Iqbal et al. also observed antifungal susceptibility differences related to genotypes [16] . Overall VGII isolates had higher in vitro MICs than VGI and VGIII. The VGIIc subgenotype was less susceptible than VGIIa, the most virulent subgenotype from the ongoing Vancouver Island (Canada) cryptococcosis outbreak. The combined results of all of the studies suggest that C. gattii molecular type VGII isolates were the least susceptible within the C. neofomans/C. gattii species complex, followed by isolates of the molecular types VGI, VNI and VNIV. In addition, differences in susceptibility were not limited to the major genotypes, but could also be found among subgenotypes. Molecular types ketoconazole, Ͻ 0.03 -0.25 μ g/ml for ravuconazole and Ͻ 0.03 -0.5 μ g/ml for voriconazole.
Comparisons of the MICs for the molecular types by Mann-Whitney test revealed that the molecular type VNI was more susceptible than VGI to itraconazole and ravuconazole ( P ϭ 0.047 and P ϭ 0.001, respectively), and more susceptible than VGII to itraconazole ( P ϭ 0.001), ravuconazole ( P Ͻ 0.001), fl uconazole ( P ϭ 0.001), albaconazole ( P Ͻ 0.001), voriconazole ( P Ͻ 0.001) and ketoconazole ( P ϭ 0.011). There were no signifi cant differences between VNI and VGII MICs to amphotericin B and 5-fl uorocytosine ( P ϭ 0.570). The comparison of the two molecular types of C. gattii , VGI and VGII revealed that VGII was less susceptible than VGI to fl uconazole ( P Ͻ 0.001), albaconazole ( P ϭ 0.004), voriconazole ( P Ͻ 0.001) and 5-fl uorocytosine ( P ϭ 0.045). The only drug for which no differences in susceptibilities was found among VGI/VGII, VGI/VNI and VGII/VNI was amphotericin B ( P -value ϭ 0.053, 0.279, 0.465, respectively).
The GM of the MICs of the VNI isolates obtained from the HIV positive patients were signifi cantly higher to fl uconazole ( P ϭ 0.025) than those recovered from HIV negative patients. There were no signifi cant differences among the VGII isolates recovered from the two host groups. The only clinical VGII isolate that had in vitro resistance to fl uconazole (MIC Ն 64) was obtained from an HIV negative patient.
Discussion
Major differences in the antifungal susceptibilities were observed among Brazilian cryptococcal isolates of the molecular types VNI, VGI and VGII. The molecular type VGII was less susceptible than VGI to four of the eight drugs tested (fl uconazole, albaconazole, voriconazole and 5-fl uorocytosine) and was less susceptible than VNI to six of the eight drugs tested (fl uconazole, albaconazole, voriconazole, 5-fl uorocytosine, itraconazole and ravuconazole). It is unknown what causes the differences in the in vitro antifungal susceptibilities among isolates of different molecular types of the C. neoformans/C. gattii species complex. Sionov et al . [17] suggested that fl uconazole resistance maybe due to chromosome duplication during prolonged azole therapy, a process that could be favoured in certain molecular types. Therefore, it seems further investigation of the genetic basis of these differences in antifungal susceptibilities of members of the Cryptococcus neoformans/C. gattii specie complex are warranted.
Fluconazole is the fi rst choice for maintenance and prophylactic therapy of cryptococcosis [19] . In this study, isolates of C. neoformans recovered from HIV positive patients were less susceptible to fl uconazole than those obtained from immunocompetent patients. In HIV positive individuals, maintenance of treatment last longer [19] , relapses are more common [20] and previous treatment of oropharyngeal candidiasis with this antifungal may have occurred [21] . In addition, C. neoformans isolates express a high rate of innate heteroresistance to fl uconazole [13] , when combined with the longer exposure to fl uconazole provide an opportunity for the emergence of resistance. This has been corroborated by Chowdhary et al . [22] who observed lower in vitro susceptibility of environmental isolates to fl uconazole than those recovered from clinical samples in India. Furthermore, they observed increased MICs to fl uconazole in serial isolates obtained after 1.5 -2.5 months of therapy. This fact may partially explain why these authors observed lower susceptibility of VGI isolates to fl uconazole when compared to VNI isolates, while in the present work VGI was only less susceptible than VNI to itraconazole and ravuconazole.
So far, the clinical implications of in vitro susceptibility differences are unknown, demanding further studies for a better understanding of the impact of the genotypes/molecular types on antifungal treatment and clinical outcome. Nevertheless, the reported data herein show a strong correlation between antifungal susceptibility and fungal genotype of members of the Cryptococcus neoformans/C. gattii complex. These fi ndings indicate clearly that the determination of the molecular type of the causative agent in specifi c cases of cryptococcosis may provide important information that will allow for better guidance in the decision making for the best treatment choice, which subsequently would lead to a better disease outcome.
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